Bispecific Antibodies for Cancer Therapy
- 19 February 2009
- journal article
- review article
- Published by Taylor & Francis in Immunotherapy
- Vol. 1 (2) , 211-222
Abstract
Bispecific antibodies, in contrast to conventional monoclonal antibodies, can bind simultaneously two different antigens. Taking advantage of this virtue, they are mostly designed for immune effector cell redirection to tumors and for radionuclide pretargeting to tumors. Bispecific antibodies of the first generation were produced by chemical cross-linking or cell-fusion technologies. More recently, the application of genetic engineering technologies gave rise to numerous formats of bispecific antibody fragments and whole IgG molecules. Because bispecific antibodies enable therapeutic strategies that are not possible with conventional monoclonal antibodies, they attract strong interest. Several bispecific antibody formats have already shown clinical efficacy in cancer patients, catalyzing efforts to translate the imaginative bispecific antibody concepts into effective therapies.Keywords
Funding Information
- Chief Scientist‘s Office of the Israel Ministry of Health
- Israel Cancer Association
- Cancer Biology Research Center of Tel Aviv University
This publication has 55 references indexed in Scilit:
- Ertumaxomab: a trifunctional antibody for breast cancer treatmentExpert Opinion on Investigational Drugs, 2008
- Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non–Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific AntibodyCancer Research, 2008
- Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of actionBlood, 2008
- Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancerBritish Journal of Cancer, 2007
- Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targetingProceedings of the National Academy of Sciences, 2006
- Antibody Pretargeting Advances Cancer Radioimmunodetection and RadioimmunotherapyJournal of Clinical Oncology, 2006
- Engineered antibody fragments and the rise of single domainsNature Biotechnology, 2005
- Recombinant approaches to IgG-like bispecific antibodiesActa Pharmacologica Sinica, 2005
- A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor ActivityJournal of Biological Chemistry, 2005
- A revival of bispecific antibodiesTrends in Biotechnology, 2004